More RFID Journal Sites: RFID Journal Espanol RFID Journal Brasil RFID Journal Events RFID Journal Awards
Retail NEWS
Text size:
T
T
T
Congress Weighs Drug Anticounterfeiting Bill
Recently introduced legislation would compel the FDA to require drugmakers to incorporate counterfeit-resistant technologies, such as RFID, into the packaging of prescription drugs.
By Mark Roberti
March 2, 2006—Congressmen Gil Gutknecht (R-Minn.) and Dan Burton (R-In.), joined by seven other members of the U.S. House of Representatives, have introduced legislation aimed at stemming the rising tide of counterfeit and fraudulent prescription drugs presently entering the United States drug supply chain. The Reducing Fraudulent and Imitation Drugs Act of 2006 calls for the incorporation of counterfeit-resistant tools, such as radio frequency identification for tracking and tracing, into the packaging of prescription drugs.
The bill, also known as H.R. 4829, states that the Secretary of Health and Human Services, who overseas a number of U.S. agencies including the U.S. Food and Drug Administration (FDA), "shall require that the packaging of any prescription drug incorporate (1) radio frequency identification (RFID) tagging technology, or similar track and trace technologies that have an equivalent function; (2) tamper-indicating technologies; and (3) blister security packaging when possible."
"Congressman Burton and I have been working on this for several years," Gutknecht says. "The Government Reform Committee had a hearing about four years ago to look at the problem of counterfeit drugs. Many people believe they are coming in from other countries—and some are—but some are originating here in the United States."
Florida has enacted a pedigree law that, starting July 1, will require pharmaceutical companies to document the chain of custody of drugs in the state. California has passed a law with similar requirements that will come into effect on Jan. 1, 2007, while other states are considering various types of pedigree laws, as well. One danger is that pharmaceutical companies will need to comply with 50 different pedigree requirements.
"If we don't get out in front of this issue, you will wind up with a patchwork of rules in every one of the 50 states," says Gutknecht. "This is clearly an issue of interstate, intrastate and international commerce. Personally, I'm disappointed the FDA hasn't acted already. This shouldn't require an act of Congress."
Gutknecht stresses that the drug supply chain in the United States is safe, but claims that because drugs have gotten so expensive, the temptation for criminals to counterfeit them is rising. There are also growing concerns among Gutknecht's constituents, and those of other legislators, that the drugs they buy might be counterfeit.
more Retail articles
March 2, 2006—Congressmen Gil Gutknecht (R-Minn.) and Dan Burton (R-In.), joined by seven other members of the U.S. House of Representatives, have introduced legislation aimed at stemming the rising tide of counterfeit and fraudulent prescription drugs presently entering the United States drug supply chain. The Reducing Fraudulent and Imitation Drugs Act of 2006 calls for the incorporation of counterfeit-resistant tools, such as radio frequency identification for tracking and tracing, into the packaging of prescription drugs.
The bill, also known as H.R. 4829, states that the Secretary of Health and Human Services, who overseas a number of U.S. agencies including the U.S. Food and Drug Administration (FDA), "shall require that the packaging of any prescription drug incorporate (1) radio frequency identification (RFID) tagging technology, or similar track and trace technologies that have an equivalent function; (2) tamper-indicating technologies; and (3) blister security packaging when possible."
|
| Congressmen Gil Gutknecht (R-Minn.) |
Florida has enacted a pedigree law that, starting July 1, will require pharmaceutical companies to document the chain of custody of drugs in the state. California has passed a law with similar requirements that will come into effect on Jan. 1, 2007, while other states are considering various types of pedigree laws, as well. One danger is that pharmaceutical companies will need to comply with 50 different pedigree requirements.
"If we don't get out in front of this issue, you will wind up with a patchwork of rules in every one of the 50 states," says Gutknecht. "This is clearly an issue of interstate, intrastate and international commerce. Personally, I'm disappointed the FDA hasn't acted already. This shouldn't require an act of Congress."
Gutknecht stresses that the drug supply chain in the United States is safe, but claims that because drugs have gotten so expensive, the temptation for criminals to counterfeit them is rising. There are also growing concerns among Gutknecht's constituents, and those of other legislators, that the drugs they buy might be counterfeit.
